Evidence map›Paper›PMID 34319568›Full record

ReviewMycopathologia2021

Emerging Fungal Threats in Cystic Fibrosis.

C Schwarz, P Eschenhagen, J P Bouchara

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mycopathologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Insights intoJournal of fungi (Basel, Switzerland) · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

C SchwarzDivision of Cystic Fibrosis, Clinic Westbrandenburg, Potsdam, Germany. Carsten.Schwarz@klinikumwb.de.
P EschenhagenCharité-Universitätsmedizin Berlin, Berlin, Germany.
J P BoucharaUniv Angers, Université de Bretagne Occidentale, CHU Angers, Groupe d'Etude des Interactions Hôte-Pathogène (GEIHP, EA3142), SFR ICAT, F-49000, Angers, France. jean-philippe.bouchara@univ-angers.fr.ORCID http://orcid.org/0000-0001-8047-9506
Charité - Universitätsmedizin Berlin · DEKlinikum Oldenburg · DEUniversité de Bretagne Occidentale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past three decades, fungal respiratory colonization and fungal respiratory infections increasingly raised concern in cystic fibrosis (CF). Reasons for this are a better knowledge of the pathogenicity of fungi, whereby detection is sought in more and more CF centers, but also improvement of detection methods. However, differences in fungal detection rates within and between geographical regions exist and indicate the need for standardization of mycological examination of respiratory secretions. The still existing lack of standardization also complicates the assessment of fungal pathogenicity, relevance of fungal detection and risk factors for fungal infections. Nevertheless, numerous studies have now been conducted on differences in detection methods, epidemiology, risk factors, pathogenicity and therapy of fungal diseases in CF. Meanwhile, some research groups now have classified fungal disease entities in CF and developed diagnostic criteria as well as therapeutic guidelines.The following review presents an overview on fungal species relevant in CF. Cultural detection methods with their respective success rates as well as susceptibility testing will be presented, and the problem of increasing azole resistance in Aspergillus fumigatus will be highlighted. Next, current data and conflicting evidence on the epidemiology and risk factors for fungal diseases in patients with CF will be discussed. Finally, an overview of fungal disease entities in CF with their current definitions, diagnostic criteria and therapeutic options will be presented.

Indexed as

Cystic FibrosisAntifungal AgentsAspergillus fumigatusFungiHumansMicrobial Sensitivity TestsPrevalenceAntifungal AgentsAntifungal susceptibility testingAspergillus clinical entities and treatmentBiological diagnosisCystic fibrosisFungal respiratory infectionsRisk factors

Identifiers

PMID34319568
OpenAlexW3186387866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.